{"id":4032,"date":"2011-04-14T13:55:00","date_gmt":"2011-04-14T13:55:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=4032"},"modified":"2021-07-09T11:22:43","modified_gmt":"2021-07-09T11:22:43","slug":"daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/","title":{"rendered":"Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yamamoto+T&amp;cauthor_id=21681409\">Takayuki Yamamoto<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21681409\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Umegae+S&amp;cauthor_id=21681409\">Satoru Umegae<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Matsumoto+K&amp;cauthor_id=21681409\">Koichi Matsumoto<\/a>, J Gastroenterol&nbsp;2011 Aug;46(8):1003-9.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>This is the first report on daily GMA in the treatment of patients with UC. Daily GMA was safe and well tolerated without serious AE. Furthermore, daily GMA was associated with rapid improvement of clinical symptoms in patients with moderately active UC. However, controlled trials are warranted to assess a definite efficacy for daily GMA therapy.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21681409\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/21681409\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Takayuki Yamamoto&nbsp;1,&nbsp;Satoru Umegae,&nbsp;Koichi Matsumoto, J Gastroenterol&nbsp;2011 Aug;46(8):1003-9. This is the first report on daily GMA in the treatment of patients with UC. Daily GMA was safe and well tolerated without serious AE. Furthermore, daily GMA was associated with rapid improvement of clinical symptoms in patients with moderately active UC. However, controlled trials are warranted to [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[147,211,273,97,274],"class_list":["post-4032","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-daily","scientific_tags-feasibility-study","scientific_tags-prospective","scientific_tags-symptoms-efficay"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Takayuki Yamamoto&nbsp;1,&nbsp;Satoru Umegae,&nbsp;Koichi Matsumoto, J Gastroenterol&nbsp;2011 Aug;46(8):1003-9. This is the first report on daily GMA in the treatment of patients with UC. Daily GMA was safe and well tolerated without serious AE. Furthermore, daily GMA was associated with rapid improvement of clinical symptoms in patients with moderately active UC. However, controlled trials are warranted to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:22:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/\",\"name\":\"Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2011-04-14T13:55:00+00:00\",\"dateModified\":\"2021-07-09T11:22:43+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/","og_locale":"es_ES","og_type":"article","og_title":"Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study - Adacyte","og_description":"Takayuki Yamamoto&nbsp;1,&nbsp;Satoru Umegae,&nbsp;Koichi Matsumoto, J Gastroenterol&nbsp;2011 Aug;46(8):1003-9. This is the first report on daily GMA in the treatment of patients with UC. Daily GMA was safe and well tolerated without serious AE. Furthermore, daily GMA was associated with rapid improvement of clinical symptoms in patients with moderately active UC. However, controlled trials are warranted to [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:22:43+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/","name":"Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2011-04-14T13:55:00+00:00","dateModified":"2021-07-09T11:22:43+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/daily-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-active-ulcerative-colitis-a-prospective-safety-and-feasibility-study\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/4032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=4032"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=4032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}